Do your gut symptoms actually meet the IBS criteria?

Rome IV (2016) raised the symptom-frequency threshold from at least 3 days per month (Rome III) to at least 1 day per week. It also dropped the requirement that pain improves with defecation, requiring instead that pain be related to defecation in either direction. The result is a stricter criterion set and a lower prevalence figure.

No. There is no positive test for IBS. Diagnosis is clinical, based on symptom criteria and exclusion of other conditions. Blood tests, faecal calprotectin, and coeliac serology are used to rule out alternatives, not to confirm IBS.

Rome IV defines four subtypes based on predominant stool form on the Bristol Stool Scale: IBS-C (constipation-predominant, hard or lumpy stool more than 25% of the time), IBS-D (diarrhoea-predominant, loose or watery stool more than 25% of the time), IBS-M (mixed pattern with both), and IBS-U (unsubtyped, where neither pattern dominates). Subtype can change over time and influences which treatments are most likely to help.

Under Rome IV criteria, global IBS prevalence is 3.8%, based on Sperber et al. (2021) who surveyed 73,076 people across 26 countries. US prevalence is 4.7% and UK prevalence is 4.2%. These figures are substantially lower than the 10 to 15% figures widely cited in media, which were based on the older and less strict Rome III criteria. Women are roughly 1.5 times more likely to meet Rome IV criteria than men. Prevalence peaks between ages 30 and 50 in most populations. If you do not meet the current criteria, that does not rule out gut symptoms that warrant medical attention.

IBS is now understood as a disorder of gut-brain interaction (DGBI), not simply a structural or motility problem. The gut and brain communicate continuously through the vagus nerve, enteric nervous system, and via neurotransmitters. People with IBS show altered visceral sensitivity (lower pain thresholds in the gut) and changes in gut motility that are modulated by the central nervous system. Stress, anxiety, and trauma history are strongly associated with IBS prevalence and severity, not because symptoms are "in the head" but because the gut-brain axis physically mediates gut function. This is why psychological therapies including gut-directed hypnotherapy and cognitive behavioural therapy have clinical trial evidence for IBS improvement.

Yes, dietary triggers are reported by up to 84% of IBS patients. The most evidence-based dietary intervention is the Low-FODMAP diet, developed at Monash University. FODMAP stands for Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols, a group of short-chain carbohydrates that are poorly absorbed in the small intestine and fermented by gut bacteria. Multiple randomised controlled trials have shown that a low-FODMAP diet reduces overall IBS symptoms in approximately 50 to 75% of patients. The diet requires a 6 to 8 week elimination phase followed by structured reintroduction to identify individual triggers. Other commonly reported triggers include caffeine, high-fat foods, alcohol, and wheat, though responses are highly individual.

IBS treatment is symptom-subtype dependent. For IBS-C, fibre supplementation, osmotic laxatives, and newer secretagogues (linaclotide, lubiprostone) have trial evidence. For IBS-D, antidiarrhoeal agents, bile acid sequestrants, and rifaximin (a non-absorbable antibiotic) are used. For overall symptom reduction across subtypes, antispasmodics, low-dose tricyclic antidepressants (which reduce visceral sensitivity independently of their mood effects), and the Low-FODMAP diet have the strongest evidence bases. Psychological therapies including gut-directed hypnotherapy and CBT have multiple positive RCTs. NICE guidelines recommend that most people with mild to moderate IBS start with dietary and lifestyle modification, with pharmacological options added for inadequate response. If your symptoms are affecting daily life, a GP can refer you to gastroenterology or a specialist dietitian.

IBS itself does not increase the risk of bowel cancer. This is an important distinction because IBS and early bowel cancer can share some symptoms, including changes in bowel habit and abdominal discomfort. The key difference is the presence of red-flag symptoms: rectal bleeding, unintentional weight loss, symptoms beginning after age 50, or a family history of bowel cancer. These features warrant urgent GP assessment regardless of whether Rome IV criteria are met. Once red flags have been excluded, an IBS diagnosis is a clinical reassurance that the underlying structural bowel is normal. Long-term follow-up studies have not found elevated colorectal cancer rates in people with IBS compared to the general population.